Urology
Volume 75, Issue 3 , Page 533 , March 2010

Reply

  • Michael L. Ganz, M.S., Ph.D.

      Affiliations

    • Abt Bio-Pharma Solutions, Inc., Lexington, Massachusetts
    • ,
  • Chris L. Pashos, Ph.D.

      Affiliations

    • Abt Bio-Pharma Solutions, Inc., Lexington, Massachusetts
    • ,
  • Amy M. Smalarz, Ph.D.

      Affiliations

    • Abt Bio-Pharma Solutions, Inc., Lexington, Massachusetts
    • ,
  • Tracey L. Krupski, M.D., M.P.H.

      Affiliations

    • Department of Urology, University of Virginia, Charlottesville, Virginia
    • ,
  • Jennifer T. Anger, M.D., M.P.H.

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, California
    • ,
  • Jim C. Hu, M.D.

      Affiliations

    • Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Kim U. Wittrup-Jensen, Ph.D.

      Affiliations

    • Bayer Schering Pharma, Berlin, Germany

Reference 

  1. Ganz ML, Smalarz A, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology. 2009;75:526–533

PII: S0090-4295(09)02309-7

doi: 10.1016/j.urology.2009.08.003

Urology
Volume 75, Issue 3 , Page 533 , March 2010

Article Tools